FST, FS
Follistatin is a protein found in the gonads that specifically blocks the release of follicle-stimulating hormone. There are two forms of the FST gene, FST317 and FST344, which produce proteins with 317 and 344 amino acids, respectively. These different forms are created through alternative splicing of the precursor mRNA. A study examining 37 potential genes for their link to polycystic ovary syndrome (PCOS) or high levels of androgens in 150 families found evidence suggesting a connection between PCOS and follistatin. Follistatin acts against the effects of ACTV and specifically prevents the production and release of follicle-stimulating hormone (FSH) from the pituitary gland.
The biological activity is assessed by the ability to counteract the inhibitory effect of ACTV on mouse MPC-11 cells. In the presence of 7.5ng/ml ACTV A, the anticipated ED50 is 100-400ng/ml, corresponding to a Specific Activity of 2,500-10,000units/mg.
FST, FS
Follistatin is a member of the transforming growth factor-beta (TGF-β) superfamily signaling modulators. It binds to and inhibits the function of several proteins, including activin, myostatin, growth differentiation factors, and bone morphogenetic proteins (BMP) . By inhibiting these proteins, follistatin regulates various biological processes such as muscle growth, inflammation, and tissue repair.
Recombinant human follistatin is produced using advanced biotechnological methods. It is typically derived from Chinese Hamster Ovary (CHO) cell lines or Spodoptera frugiperda (Sf 21) cells using baculovirus expression systems . The recombinant form is designed to mimic the natural protein’s structure and function, making it useful for research and therapeutic applications.
Recombinant human follistatin has several applications in scientific research and medicine: